Aripiprazole CAS 129722-12-9 Ịdị ọcha> 99.0% (HPLC) API

Aripiprazole (CAS: 129722-12-9) bụ ụdị ọhụrụ nke nnukwu lipid soluble quinoline ewepụtara, njirimara ya na ọgwụ ọgwụ bụ na ọ bụghị naanị postsynaptic dopamine D2 antagonist, kamakwa presynaptic dopamine D2 agonist, ọ nwekwara ike. na-akpali ndị na-anabata D1, D3, D4.Aripiprazole bụ ọgbọ nke abụọ atypical antipsychotic na mgbochi ịda mbà n'obi nwere ọrụ agonist akụkụ na dopamine D2 na serotonin 5-HT1A receptors na antagonist ọrụ na serotonin 5-HT2A receptors.Ụkpụrụ Ki bụ 0.34 nM, 0.8 nM, 1.7 nM, na 3.4 nM, n'otu n'otu, maka dopamine D2 na D3, serotonin 5-HT1A na 5-HT2A.A na-eji Aripiprazole eme ihe maka ọgwụgwọ schizophrenia na ọrịa uche metụtara ya.Bristol-Myers Squibb na Otsuka Pharmaceutical Company kwupụtara na European Union akwadola Abilify (Aripiprazole) na ọgwụgwọ nke ngwa ndepụta schizophrenia.Schizophrenia na-emetụta 1% nke ọnụ ọgụgụ ụwa, yana karịa na ndị toro eto.Schizophrenia na-emetụta echiche, njikwa mmetụta uche na ikike ime mkpebi nke onye ọrịa.Ndị ọrịa na-arịa ọrịa schizophrenia ga-enwe mgbaàmà dị ka ihe na-egbuke egbuke na aghụghọ, ndị ọrịa nwere mgbaàmà na-adịghị mma bụ nkwụsị nke ọha mmadụ, enweghị mgbanwe mmetụta uche.Na 2002 FDA kwadoro Abilify maka ọgwụgwọ schizophrenia, nke nwere ikike usoro ọgwụgwọ ise: 5 mg, 10 mg, 15 mg, 20 mg na 30 mg, kemgbe nkwenye ya.